



PROGRAM

0800 **Registration Open**

0830 **Coffee, Introductions and welcome**

Evolving models of Care, MDTs and The APTCaR collaboration

Clinical Associate Professor Paul Benitez-Aguirre, Sydney Children's Hospital Network, NSW

0845 **Update on Thyroid Cancers pathological classification, challenges and evolution: A global perspective**

Professor Anthony J Gill AM, Royal North Shore Hospital, NSW

Professor Anthony J Gill AM (MBBS MD FRCPA) is Professor of Surgical Pathology at the University of Sydney, a senior staff specialist in anatomical pathology at the Royal North Shore Hospital in Sydney and chairman of the Australian Pancreatic Genome Initiative (APGI). His scope of clinical practice includes both anatomical (surgical and cytological) pathology and targeted molecular testing of tumours, with an emphasis on biomarker development and companion diagnostic testing for targeted therapies.

0930 **Molecular diagnostics of thyroid nodules and cancer. The impact of genomic profiling on risk stratification**

Dr Vivek Rathi, Lifestrands Diagnostics, VIC

Dr Vivek Rathi is a Molecular and Anatomical Pathologist and Medical Director at Lifestrands diagnostics. He has a keen interest in molecular assay design, validation, and quality control. His dual qualification as an Anatomical and Molecular Pathologist enables him to tackle high level translational research challenges including spatial genomics, understanding complex interactions between tumour and microenvironment, disease heterogeneity, gene expression, and cancer pathway profiling.

1015 **Morning tea**

1045 **Imaging Diagnostics – from thyroid nodule challenges to thyroid cancer staging.**

Dr David Chung, Sydney Children's Hospital Network, NSW

Dr David Chung is a Senior Staff Specialist at the SCHN with extensive expertise in neck and thyroid sonology. He is an expert in diagnostic and therapeutic aspects of Nuclear Medicine working in public and private sectors. He is a keen teacher and a Lecturer at the University of Sydney and Macquarie University.

1115 **Challenges in Paediatric Thyroid Cancer Surgery - Surgical approaches and innovation**

Dr Catherine Langusch, The Children's Hospital at Westmead, NSW

Dr Catherine Langusch is a General Paediatric Surgeon who works as a Visiting Medical Officer at The Children's Hospital at Westmead, Royal Prince Alfred Hospital and Nepean Hospital. She has a special interest in head and neck surgery, including thyroid and parathyroid conditions.

1145 **Australasian Paediatric Thyroid Cancer Collaborative: Current state of play and future potential**

Clinical Associate Professor Paul Benitez-Aguirre, Sydney Children's Hospital Network

Join us for a session covering the evolution of service provision, the need for standardising models of care for paediatric thyroid cancer and the role of The Australian Collaborative Community. We will also cover the impact of the molecular revolution on prognosis and model of care, adjuvant and neoadjuvant targeted therapies.

1215 Forum questions

1230 **Lunch**

1300	<p>Nuclear medicine diagnostics and therapy in paediatric thyroid cancer and lessons from adult studies <i>Professor Liz Thomas, Sir Charles Gardiner Hospital, WA & Dr Ian Jong, Monash Health, Vic</i></p> <p>Illustrative cases and discussion with experts in diagnostic and therapeutic aspects of Nuclear Medicine in Paediatric and Adult care working across public and private services. A review of current practice and the changing landscape of nuclear medicine in paediatric and adult thyroid cancer.</p>
------	---

1340	<p>Molecular assessment of paediatric thyroid cancer: The Australian Oncology Experience ANZCHOG and The Zero Collaboration <i>Professor Antoinette Anazodo, Sydney Children's Hospital, NSW</i></p> <p>Professor Antoinette Anazodo trained in paediatric and adolescent oncologist. Prof Anazodo was appointed as Director, Adolescent and Young Adult Cancer at Sydney Children's Hospital, Randwick and Prince of Wales Hospital in October 2010. She is developing the AYA cancer service to ensure all AYA patients have access to appropriate age and tumour specific medical treatment as well as ensuring they benefit from psychosocial assessment and care navigation through treatment.</p>
------	---

1410	<p>Paediatric thyroid cancer and familial cancer predisposition cohorts - The personal, familial and ethical challenges and considerations <i>Dr Noemi Fuentes-Bolaños, University of New South Wales, NSW, Dr Bhavna Padhye, Children's Hospital at Westmead and Professor Kathy Tucker, Sydney Childrens Hospital, NSW</i></p> <p>Join some of our leading experts in thyroid cancer and familial cancer genetics for an update and discussion panel on the evolving molecular revolution, the opportunities, prognostic and treatment implications as well as the challenges, both ethical and practical, of such information. The need for a cohesive national approach.</p>
------	--

1500	Afternoon tea
-------------	----------------------

International updates in thyroid cancer.
 Clinical and research perspective from childhood to adult care

1530	<p>A comprehensive approach to the management of paediatric thyroid nodules and cancer. An update on the 2025 ATA Management Guidelines for Paediatric Thyroid Carcinoma and what lays ahead <i>Professor Andrew Bauer, Children's Hospital of Philadelphia, USA</i></p> <p>Join Prof Andrew Bauer, Medical Director, Pediatric Thyroid Center, Children's Hospital of Philadelphia (CHOP) as he takes us on a journey on the practical approach to thyroid carcinoma. From the bedside to the most relevant research and how this has shaped the ATA 2025 guidelines. The current collaborations and what lays ahead.</p>
------	--

1620	<p>An update on lessons from adult studies , the chasm of transition and how we can optimise long term outcomes/follow up <i>Associate Professor Matti Gild, University of Sydney & Royal North Shore Hospital, NSW</i></p> <p>Join Associate Professor Matti Gild - Associate Professor at the University of Sydney and Endocrinologist at Royal North Shore Hospital as she gives us an update on latest targeted therapies studies and relevant lessons and perspectives. Matti will also discuss the transition of care and how we can contribute to optimising long term follow up.</p>
------	--

1700	<p>Closing session <i>Clinical Associate Professor Paul Benitez-Aguirre, Sydney Children's Hospital Network</i></p>
------	---

1730	Networking drinks
-------------	--------------------------

